Avadel Pharmaceuticals' Lumryz Is Now Commercially Available In US. Lumryz Is An Extended-Release Formulation Of Sodium Oxybate Indicated To Be Taken Once At Bedtime For Cataplexy Or Excessive Daytime Sleepiness In Adults With Narcolepsy
Portfolio Pulse from Benzinga Newsdesk
Avadel Pharmaceuticals has launched Lumryz, an extended-release formulation of sodium oxybate, in the US market. Lumryz is designed to treat cataplexy or excessive daytime sleepiness in adults with narcolepsy.
June 05, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avadel Pharmaceuticals' Lumryz is now commercially available in the US, potentially increasing the company's revenues and stock price.
The commercial availability of Lumryz in the US market is a significant milestone for Avadel Pharmaceuticals. As a new product, it has the potential to increase the company's revenues and positively impact its stock price in the short term. The news is highly relevant and important for investors in AVDL.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100